Merck Common (New) (MRK) closed at $144.46 on November 16, 2026, down 2.2% from the previous close, on volume of 6,338,447 shares (30-day average 9,423,469).
Data as of November 16, 2026.
16-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 21, 2026 | Call Spread | 30-Oct-26160 : 170 C | 16,190 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
White House getting antsy over FDA commissioner nominee Heidi Overton
Seeking Alpha News (Mon, 16-Nov 5:32 PM ET)
3 ETFs with Room for 10% or More Gains, According to AI Analyst
TipRanks (Mon, 16-Nov 4:11 PM ET)
Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Palatin Technologies (PTN)
TipRanks (Mon, 16-Nov 11:00 AM ET)
Merck & Company (MRK) Gets a Buy from Barclays
TipRanks (Mon, 16-Nov 4:26 AM ET)
SA Asks: What are the most attractive Big Pharma stocks right now?
Seeking Alpha News (Sun, 15-Nov 2:56 PM ET)
Measles cases rise to over 5,400 across US
Seeking Alpha News (Fri, 13-Nov 3:21 PM ET)
Merck gains EMA panel endorsement for expanded use of Enflonsia in infants
Seeking Alpha News (Fri, 13-Nov 12:07 PM ET)
Business Wire (Fri, 13-Nov 6:40 AM ET)
Business Wire (Fri, 13-Nov 6:35 AM ET)
TipRanks (Thu, 12-Nov 8:50 AM ET)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Merck Common (New) trades on the NYSE stock market under the symbol MRK.
As of November 16, 2026, MRK stock price declined to $144.46 with 6,338,447 million shares trading.
MRK has a beta of -0.34, meaning it tends to be less sensitive to market movements. MRK has a correlation of 0.02 to the broad based SPY ETF.
MRK has a market cap of $356.41 billion. This is considered a Mega Cap stock.
Last quarter Merck Common (New) reported $18 billion in Revenue and $2.49 earnings per share. This beat revenue expectation by $763 million and exceeded earnings estimates by $.39.
In the last 3 years, MRK traded as high as $156.92 and as low as $73.31.
The top ETF exchange traded funds that MRK belongs to (by Net Assets): VTI, VOO, IVV, SCHD, SPY.
MRK has outperformed the market in the last year with a return of +59.1%, while the SPY ETF gained +11.3%. In the last 3 month period, MRK beat the market returning +7.0%, while SPY returned -4.4%. However, in the most recent 2 weeks MRK has underperformed the stock market by returning -2.6%, while SPY returned -1.6%.
MRK support price is $144.50 and resistance is $151.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRK shares will trade within this expected range on the day.